Manara - Qatar Research Repository
Browse

Real-world experience of ocrelizumab in multiple sclerosis in an Arab population

Download (1.28 MB)
journal contribution
submitted on 2025-05-08, 09:40 and posted on 2025-05-08, 09:42 authored by Beatriz Garcia-Cañibano, Sami Ouanes, Gowrii Saswathy Ganesan, Wajiha Yousuf, Basel Humos, Tehniyat Baig, Faiza Ibrahim, Rajvir Singh, Dirk Deleu

Objective

Pivotal clinical trials revealed good clinical efficiency of ocrelizumab while having a good safety profile in the management of multiple sclerosis (MS). However, real-world data of ocrelizumab in daily clinical practice remain scarce. The aim of this study was to evaluate the preliminary safety profile and effectiveness of ocrelizumab treatment for MS in an Arab population in a real-world clinical setting.

Methods

In this retrospective single-center observational study in Qatar, we reviewed the medical records and analyzed the clinical and MRI data of all patients with relapsing-remitting MS (RRMS) and active secondary progressive MS (aSPMS)—between October 2017 through December 2020—who had received at least one infusion of ocrelizumab (Q-OCRE).

Results

A total of 60 MS patients were included (57 with RRMS, three SPMS). The Median follow-up period was 19 months (range, 1–32). The most common reason for switching to ocrelizumab was increased disease activity and three-quarters of the patients were on a previous disease-modifying drug (DMD). No evidence of disease activity (NEDA) status at year 1 was achieved in 73% of the cohort. Mild infusion-related reactions (IRR) and infections were reported (mainly upper respiratory tract infections followed by urinary tract infection) with a declining percentage over the follow-up applications. No severe side effects were observed.

Conclusion

Our real-world experience confirms good efficacy, tolerability, and safety of ocrelizumab in our Arab population.

Other Information

Published in: Journal of Drug Assessment
License: http://creativecommons.org/licenses/by-nc/4.0/
See article on publisher's website: https://dx.doi.org/10.1080/21556660.2021.1989193

Funding

Open Access funding provided by the Qatar National Library.

History

Language

  • English

Publisher

Taylor & Francis

Publication Year

  • 2021

License statement

This Item is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License

Institution affiliated with

  • Hamad Medical Corporation
  • Heart Hospital - HMC
  • Cardiology Research Center - Heart Hospital
  • Weill Cornell Medicine - Qatar

Geographic coverage

Qatar

Usage metrics

    Hamad Medical Corporation

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC